HH3806-A101
A Phase I, Open-label, Multicenter, First in Human Study to Evaluate the Safety and Tolerability of HH3806 in Patients with Advanced Malignancies
Trial summary:
This study is evaluating how safe, tolerable and effective a new potential treatment drug called HH3806 is in people with advanced solid cancer or relapsed/refractory non-Hodgkin’s lymphomas.
Receptor status / problem studied:
Inclusion criteria
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- You have had treatment, but your cancer has come back.
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
Exclusion criteria
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Open for recruitment
Trial Title
HH3806-A101
Diagnosis
Advanced solid tumours
Type of trial
Pharmaceutical
Type of treatement
Medical Oncology
Phase
I
Locations
Investigators
Principal Investigator